Partial heart transplantation using ice-free cryopreservation – Homovitals 2.0

Authors

  • Ulrich Stock Dept Cardiothoracic Surgery, Fiona Stanley Hospital, Murdoch, Australia & University of Western Australia, Perth, Australia & Medical University South Carolina, Charleston, SC, USA
  • Kelvin Brockbank Medical University South Carolina, Charleston, SC, USA & Clemson University, Clemson, SC, USA & Tissue Testing Technologies LLC, Charleston, SC, USA
  • Taufiek Konrad Rajab University of Arkansas, Medical Sciences,, Arkansas, AR, USA & Children’s Hospital Arkansas, Arkansas, AR,, USA

DOI:

https://doi.org/10.21542/gcsp.2025.hvbte.71

Abstract

Introduction: Contemporary heart valve substitutes allow satisfactory replacement option for the older patients (>60 years). For the paediatric, adolescent and young adult population current heart valve replacements lack the ability to grow and regenerate, requiring multiple repeat surgeries. Partial heart transplantation (PHT) represents a new heart valve replacement method overcoming the limitations of current valve substitutes by providing a living heart valve. The limitation of PHT is the short shelf life (48hours) from procurement to implantation.

Methods: Our group has developed an ice-free cryopreservation (IFC) technique (vitrification) to preserve vital extracellular matrix architecture in human heart valves for transplantation. Shortcoming of the original vitrification protocol was a high cytotoxicity of the required chemical supplements. 

Results: We have developed a modified vitrification protocol with adjusted chemical supplements maintaining ECM integrity and viability allowing long-term storage of ovine and porcine PHT valves.

Conclusion: PHT combined with a modified IFC protocol offers an attractive pathway to overcome contemporary limitations of allograft heart valves. This next generation of homovitals allows lomg-term storage and preservation of crucial ECM integrity and cellular viability

Published

2025-10-06